RESEARCH ACTIVITY

Relevant publications during the last three years

  1. Alevroudis E, Spei ME, Chatziioannou SN, Tsoli M, Wallin G, Kaltsas G, Daskalakis K. Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis. Cancers (Basel). 2021 Apr 10;13(8):1813. doi: 10.3390/cancers13081813.
  2. Partelli S, Ramage JK, Massironi S, Jerbi A, Kim HB, et al. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study. Front Med (Lausanne). 2020 Dec 23;7: 598438. doi: 10.3389/fmed.2020.598438.
  3. Alexandraki KI, Kaltsatou M, Kyriakopoulos G, Mavroeidi V, Kostopoulou A, Atlan K, Theocharis S, Rindi G, Grossman AB, Grozinsky-Glasberg S, Kaltsas GA. Distinctive features of pancreatic neuroendocrine neoplasms exhibiting an increment in proliferative activity during the course of the disease. Endocrine. 2020 Nov 11. doi: 10.1007/s12020-020-02540-w.
  4. Koumarianou A, Kaltsas G. Surufatinib – a novel oral agent for neuroendocrine tumours. Nat Rev Endocrinol. 2020 Oct 30. doi: 10.1038/s41574-020-00439-0.
  5. Alexandraki KI, Kaltsas G, Grozinsky-Glasberg S, Oleinikov K, Kos-Kudła B, Kogut A, Srirajaskanthan R, Pizanias M, Poulia KA, Ferreira C, Weickert MO, Daskalakis K. The effect of prophylactic surgery in survival and HRQoL in appendiceal NEN. 2020 Oct;70(1):178-186. doi: 10.1007/s12020-020-02356-8.
  6. Tsoli M, Dimitriadis GK, Androulakis II, Kaltsas G, Grossman A. Paraneoplastic Syndromes Related to Neuroendocrine Tumors. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, Grossman A, Hershman JM, Hofland HJ, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Purnell J, Singer F, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2020 Sep 26.
  7. Tsoli M, Spei ME, Wallin G, Kaltsas G, Daskalakis K. Association of a Palliative Surgical Approach to Stage IV Pancreatic Neuroendocrine Neoplasms with Survival: A Systematic Review and Meta-Analysis. Cancers (Basel). 2020 Aug 11;12(8):2246. doi: 10.3390/cancers12082246.
  8. Koumarianou A, Alexandraki KI, Wallin G, Kaltsas G, Daskalakis K. Pathogenesis and Clinical Management of Mesenteric Fibrosis in Small Intestinal Neuroendocine Neoplasms: A Systematic Review. J Clin Med. 2020 Jun 8;9(6):1777. doi: 10.3390/jcm9061777.
  9. Koumarianou A, Pectasides D, Koliou GA, Dionysopoulos D, Kolomodi D, Poulios C, Skondra M, Sgouros J, Pentheroudakis G, Kaltsas G, Fountzilas G. Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study. Biology (Basel). 2020 Mar 9;9(3). doi: 10.3390/biology9030051.
  10. Daskalakis K, Alexandraki KI, Kloukina I, Kassi E, Felekouras E, Xingi E, Pagakis SN, Tsolakis AV, Andreakos E, Kaltsas G, Kambas K. Increased autophagy/mitophagy levels in primary tumours of patients with pancreatic neuroendocrine neoplasms. 2020 Feb 29. doi: 10.1007/s12020-020-02228-1.
  11. Tsoli M, Alexandraki K, Xanthopoulos C, Kassi E, Kaltsas G. Medical Treatment of Gastrointestinal Neuroendocrine Neoplasms. Horm Metab Res. 2020 Feb 27. doi: 10.1055/a-1110-7251.
  12. Öberg K, Califano A, Strosberg JR, Ma S, Pape U, Bodei L, Kaltsas G, Toumpanakis C, Goldenring JR, Frilling A, Paulson S. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol. 2020 Feb;31(2):202-212. doi: 10.1016/j.annonc.2019.11.003.
  13. Alexandraki KI, Daskalakis K, Tsoli M, Grossman AB, Kaltsas GA. Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Trends Endocrinol Metab. 2020 Mar;31(3):239-255. doi: 10.1016/j.tem.2019.11.003.
  14. Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020 Apr 1;41(2). doi: 10.1210/endrev/bnz004.
  15. Daskalakis K, Alexandraki K, Kassi E, Tsoli M, Angelousi A, Ragkousi A, Kaltsas G. The risk of lymph node metastases and their impact on survival in patients with appendiceal neuroendocrine neoplasms: a systematic review and meta-analysis of adult and paediatric patients. Endocrine. 2020 Jan;67(1):20-34. doi: 10.1007/s12020-019-02072-y.
  16. Chatzellis E, Daskalakis K, Angelousi A, Tsoli M, Alexandraki KI, Wachula E, Meirovitz A, Maimon O, Grozinsky-Glasberg S, Gross D, Kos-Kudła B, Koumarianou A, Kaltsas G. Authors’ Response to the Letter by Lamarca et al. Entitled “Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration” Regarding “Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms”. 2020;110(1-2):158-160. doi: 10.1159/000503999.
  17. Tsolakis AV, Ragkousi A, Vujasinovic M, Kaltsas G, Daskalakis K. Gastric neuroendocrine neoplasms type 1: A systematic review and meta-analysis. World J Gastroenterol. 2019 Sep 21;25(35):5376-5387. doi: 10.3748/wjg.v25.i35.5376.
  18. Daskalakis K, Tsoli M, Alexandraki KI, Angelousi A, Chatzellis E, Tsolakis AV, Karoumpalis I, Kolomodi D, Kassi E, Kaltsas G. Magnetic Resonance Imaging or Endoscopic Ultrasonography for Detection and Surveillance of Pancreatic Neuroendocrine Neoplasms in Patients with Multiple Endocrine Neoplasia Type 1? Horm Metab Res. 2019 Sep;51(9):580-585. doi: 10.1055/a-0931-7005.
  19. Angelousi A, Koffas A, Grozinsky-Glasberg S, Gertner J, Kassi E, Alexandraki K, Caplin ME, Kaltsas G, Toumpanakis C. Diagnostic and Management Challenges in Vasoactive Intestinal Peptide Secreting Tumors: A Series of 15 Patients. 2019 Aug;48(7):934-942. doi: 10.1097/MPA.0000000000001347.
  20. Daskalakis K, Tsoli M, Karapanagioti A, Chrysochoou M, Thomas D, Sougioultzis S, Karoumpalis I, Kaltsas GA, Alexandraki KI. Recurrence and metastatic potential in Type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf). 2019 Oct;91(4):534-543. doi: 10.1111/cen.14055.
  21. Chatzellis E, Angelousi A, Daskalakis K, Tsoli M, Alexandraki KI, Wachuła E, Meirovitz A, Maimon O, Grozinsky-Glasberg S, Gross D, Kos-Kudła B, Koumarianou A, Kaltsas G. Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms. 2019;109(4):333-345. doi: 10.1159/000500135.
  22. Daskalakis K, Tsoli M, Angelousi A, Kassi E, Alexandraki KI, Kolomodi D, Kaltsas G, Koumarianou A. Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms. Endocr Connect. 2019 Jun;8(6):641-653. doi: 10.1530/EC-19-0134.
  23. Alexandraki KI, Tsoli M, Kyriakopoulos G, Angelousi A, Nikolopoulos G, Kolomodi D, Kaltsas GA. Current concepts in the diagnosis and management of neuroendocrine neoplasms of unknown primary origin. Minerva Endocrinol. 2019 Dec;44(4):378-386. doi: 10.23736/S0391-1977.19.03012-8.
  24. Angelousi A, Kassi E, Ansari-Nasiri N, Randeva H, Kaltsas G, Chrousos G. Clock genes and cancer development in particular in endocrine tissues. Endocr Relat Cancer. 2019 Jun;26(6):R305-R317. doi: 10.1530/ERC-19-0094.
  25. Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G. Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab. 2018 Oct 31;10:2042018818804698. doi:10.1177/2042018818804698.
  26. Daskalakis K, Tsoli M, Srirajaskanthan R, Chatzellis E, Alexandraki K, Angelousi A, Pizanias M, Randeva H, Kaltsas G, Weickert MO. Lung Metastases in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Neoplasms: An Appraisal of the Validity of Thoracic Imaging Surveillance. 2019;108(4):308-316. doi: 10.1159/000497183.
  27. Alexandraki KI, Pizanias M, Uri I, Thomas D, Page T, Kolomodi D, Low CS, Adesanya O, Tsoli M, Gross DJ, Randeva H, Srirajaskanthan R, Grozinsky-Glasberg S, Kaltsas G, Weickert MO. The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice. 2019 Jun;64(3):690-701. doi: 10.1007/s12020-019-01838-8.
  28. Jensen RT, Bodei L, Capdevila J, Couvelard A, Falconi M, Glasberg S, Kloppel G, Lamberts S, Peeters M, Rindi G, Rinke A, Rothmund M, Sundin A, Welin S, Fazio N; The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. 2019;108(1):26-36. doi: 10.1159/000494258.
  29. Daskalakis K, Chatzelis E, Tsoli M, Papadopoulou-Marketou N, Dimitriadis GK, Tsolakis AV, Kaltsas G. Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms. 2019 May;64(2):384-392. doi: 10.1007/s12020-018-1773-3.
  30. Baudin E, Hayes AR, Scoazec JY, Filosso PL, Lim E, Kaltsas G, Frilling A, Chen J, Kos-Kudła B, Gorbunova V, Wiedenmann B, Nieveen van Dijkum E, Ćwikła JB, Falkerby J, Valle JW, Kulke MH, Caplin ME; ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms. 2019;108(1):7-17. doi: 10.1159/000493980..
  31. Toumpanakis C, Fazio N, Tiensuu Janson E, Hörsch D, Pascher A, Reed N, O Apos Toole D, Nieveen van Dijkum E, Partelli S, Rinke A, Kos-Kudla B, Costa F, Pape UF, Grozinsky-Glasberg S, Scoazec JY; The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Unmet Needs in Appendiceal Neuroendocrine Neoplasms. 2019;108(1):37-44. doi: 10.1159/000493894.
  32. Ramage JK, Valle JW, Nieveen van Dijkum EJM, Sundin A, Pascher A, Couvelard A, Kloeppel G; the ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need. 2019;108(1):45-53. doi: 10.1159/000493767..
  33. Capdevila J, Bodei L, Davies P, Gorbounova V, Jensen RT, Knigge UP, Krejs GJ, Krenning E, O’Connor JM, Peeters M, Rindi G, Salazar R, Vullierme MP, Pavel ME; ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms. 2019;108(1):18-25. doi: 10.1159/000493319.
  34. Sorbye H, Baudin E, Borbath I, Caplin M, Chen J, Cwikla JB, Frilling A, Grossman A, Kaltsas G, Scarpa A, Welin S, Garcia-Carbonero R; ENETS 2016 Munich Advisory Board Participants. Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). 2019;108(1):54-62. doi: 10.1159/000493318.
  35. Daskalakis K, Kaltsas G, Öberg K, Tsolakis AV. Lung Carcinoids: Long-Term Surgical Results and the Lack of Prognostic Value of Somatostatin Receptors and Other Novel Immunohistochemical Markers. 2018;107(4):355-365. doi: 10.1159/000493944.
  36. Grozinsky-Glasberg S, Alexandraki KI, Angelousi A, Chatzellis E, Sougioultzis S, Kaltsas G. Gastric Carcinoids. Endocrinol Metab Clin North Am. 2018 Sep;47(3):645-660. doi: 10.1016/j.ecl.2018.04.013.
  37. Kyriakopoulos G, Mavroeidi V, Chatzellis E, Kaltsas GA, Alexandraki KI. Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. Ann Transl Med. 2018 Jun;6(12):252. doi: 10.21037/atm.2018.06.27.
  38. Tsoukalas N, Baxevanos P, Aravantinou-Fatorou E, Tolia M, Galanopoulos M, Tsapakidis K, Kyrgias G, Toumpanakis C, Kaltsas G. Advances on systemic treatment for lung neuroendocrine neoplasms. Ann Transl Med. 2018 Apr;6(8):146. doi: 10.21037/atm.2018.04.03.
  39. Kanakis GA, Grimelius L, Papaioannou D, Kaltsas G, Tsolakis AV. Can insulin-like growth factor 1 (IGF-1), IGF-1 receptor connective tissue growth factor and Ki-67 labelling index have a prognostic role in pulmonary carcinoids? 2018 Apr 27;9(32):22653-22664. doi: 10.18632/oncotarget.25203.
  40. Robbins HL, Symington M, Mosterman B, Goodby J, Davies L, Dimitriadis GK, Kaltsas G, Randeva HS, Weickert MO. Supplementation of Vitamin D Deficiency in Patients with Neuroendocrine Tumors Using Over-the-Counter Vitamin D3 Preparations. Nutr Cancer. 2018 Jul;70(5):748-754. doi: 10.1080/01635581.2018.1470650.
  41. Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. Clin Ther. 2018 Jun;40(6):952-962.e2. doi: 10.1016/j.clinthera.2018.04.006..
  42. Grozinsky-Glasberg S, Kaltsas G, Kaltsatou M, Lev-Cohain N, Klimov A, Vergadis V, Uri I, Bloom AI, Gross DJ. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice. 2018 Jun;60(3):499-509. doi: 10.1007/s12020-018-1537-0.

RESEARCH PROTOCOLS

Study of the expression of clock genes in adrenal tumors, in collaboration with the Laboratory of Biological Chemistry – Medical School (collaborator: Eva Kassi)

Study of Transcription Factors in Neuroendocrine Tumors of the Gastrointestinal System

  1. Study of Clock genes disorders in patients with autoimmune atrophic gastritis, gastric enterochromatin cell type hyperplasia and gastric carcinoids type 1, in collaboration with the Laboratory of Biological Chemistry – Medical School (collaborator: Eva Kassi)
  2. Study of the role of the autophagy pathway in the Neuroendocrine Tumors of the Pancreas in collaboration with the Research Center Clinic, Experimental Surgery & Translation Research – Institute of Biological Research of the Academy of Athens (collaborator: Evagelos Andreakos)

Epigenetic changes in osteoporosis, in collaboration with the Biomedical Research Laboratory – 251 Aviation General Hospital (collaborator: Polyzois Makras)

Study of the effect of malnutrition on the clinical outcome of patients with neuroendocrine tumors

Sarcopenia and Neuroendocrine tumors

The clinical significance of metastatic bone disease in patients with advanced Gastrointestinal Neuroendocrine Tumors.

Long term follow-up in patients with Appendiceal Neuroendocrine Tumors (Appendiceal NEN)

Metastatic Gastric Neuroendocrine Neoplasms (NENs) type 1

Tumorigenesis in Pituitary

Comparison of Magnetic Resonance Imaging (MRI) and Endoscopic Ultarsonography (EUS) in patients with Multiple Endocrine Neoplasia type 1 (MEN1)

Pulmonary metastases in patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP NET)

Effect of Neuroendocrine tumors in Bone Metabolism

Capecitabine and Temozolomide (CAPTEM) in NETs

CLINICAL TRIALS

European Observational Study on Pasireotide LAR in Acromegaly – ACRONIS

CODE: CSOM230CIC05

Sponsor: Novartis Pharma Services AG

Study on the efficacy and safety of Afinitor® (everolimus) in patients with non-surgical or metastatic pancreatic neuroendocrine tumors G1 or G2, with progressive disease – PROTOR

CODE: CRAD001PGR07

Sponsor: Novartis Pharma Services AG

A double-blind, placebo-controlled, randomized withdrawal study after open-label therapy to evaluate the safety and efficacy of levocetoconazole (2S, 4R-ketoconazole) in the treatment of Endogenous Cushing’s Syndrome

CODE: COR-2017-01

Sponsor: Cortendo AB

ASPEN study: A Prospective Evaluation of the Management of Sporadic Asymptomatic Non-functioning Pancreatic Neuroendocrine Neoplasms ≤2

Evaluation of the effect of denosumab in adult patients with Langerhans cell histiocytosis (LCH): a multicenter, single-stranded, open-label clinical trial

CODE: 20159460

Adaptation of the existing EORTC QLQ-GINET21 module to develop a specific module for use in patients with Pancreatic Neuroendocrine Tumor, Phases I to III

 

Leave a Reply

Your email address will not be published.

Top